Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 714M 618M 579M 529M 994M 68.08B 1.01B 6.82B 2.66B 34.09B 2.68B 2.62B 114B P/E 2026 *
3.53x
P/E 2027 * 3.43x
Enterprise Value 714M 618M 579M 529M 994M 68.08B 1.01B 6.82B 2.66B 34.09B 2.68B 2.62B 114B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.45x
Free-Float
96.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week+4.10%
Current month+2.13%
1 month-3.36%
3 months+5.62%
6 months-6.29%
Current year+28.19%
1 week 4.04
Extreme 4.04
4.5
1 month 3.55
Extreme 3.55
4.59
Current year 2.95
Extreme 2.95
5.78
1 year 1.01
Extreme 1.01
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 11/03/2021
Director of Finance/CFO 44 14/05/2026
Chief Tech/Sci/R&D Officer - 19/07/2026
Director TitleAgeSince
Director/Board Member 68 03/06/2021
Chairman 61 31/03/2019
Director/Board Member 56 31/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/07/26 Free

Chief Technology Officer

137,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-127,890 0.0777%
23/02/26 Sell

Chief Executive Officer

198,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%+4.10%+339.69%-57.10% 714M
+1.92%+3.58%+65.53%+23.72% 328B
-0.38%-4.27%+25.12%-14.52% 70.25B
-0.81%+21.77%+58.95%+132.66% 11.55B
+0.79%+3.92%-0.70%-2.17% 8.52B
-2.54%+7.56%-10.73%-6.86% 4.88B
-2.92%+10.65%-25.14%+15.26% 4.37B
-0.76%+13.44%+2.89%+48.08% 4.22B
+2.11%+2.05%+16.08%+50.11% 2.78B
-2.00%-0.14%-1.79%-1.14% 2.24B
Average -0.40%+5.94%+46.99%+18.80% 43.75B
Weighted average by Cap. +1.32%+3.08%+55.00%+19.67%

Financials

2026 *2027 *
Net sales 472M 409M 383M 349M 656M 44.98B 667M 4.5B 1.76B 22.52B 1.77B 1.73B 75.1B 494M 428M 401M 366M 687M 47.11B 698M 4.72B 1.84B 23.59B 1.85B 1.81B 78.65B
Net income 203M 176M 165M 151M 283M 19.39B 287M 1.94B 759M 9.71B 763M 747M 32.37B 220M 190M 178M 163M 306M 20.97B 311M 2.1B 821M 10.5B 826M 808M 35.01B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
12/08/26 US$4.320 +0.47% 2,721,196
11/08/26 US$4.300 +6.17% 1,929,785
10/08/26 US$4.050 -6.25% 2,184,399
07/08/26 US$4.320 +1.41% 1,843,075
06/08/26 US$4.260 +2.65% 3,361,970
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.320USD
Average target price
6.100USD
Spread / Average Target
+41.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock